Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - ibandronic acid - film-coated tablet - 150 milligram(s) - bisphosphonates; ibandronic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - ibandronic sodium monohydrate - film-coated tablet - 150 milligram(s) - bisphosphonates; ibandronic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - ibandronate sodium monohydrate - film coated tablet - 150 base milligrams - bisphosphonates

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - ibandronic acid ( as monosodium monohydrate 56.25mg) - tablet, film coated - 50mg - ibandronic acid ( as monosodium monohydrate 56.25mg) 50mg

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - ibandronic acid (as monosodium monohydrate 3.375mg) - injection, solution - 3mg/3ml - ibandronic acid (as monosodium monohydrate 3.375mg) 3mg/3ml

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - ibandronic acid (ibandronate form) - tablet, film coated - 168.75 mg - ibandronic acid (ibandronate form) 168.75 mg

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - ibandronic acid (ibandronate form) - tablet, film coated - 2.5mg (2.813mg)

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - ibandronic acid, monosodium salt, monohydrate eqv. to ibandronic acid - injection - 1mg/ml - ibandronic acid, monosodium salt, monohydrate eqv. to ibandronic acid 1mg/ml

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - ibandronic acid - film-coated tablet - ibandronic acid 150 mg - drugs for treatment of bone diseases

European Union - English - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - ibandronic acid - osteoporosis, postmenopausal - drugs for treatment of bone diseases - treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1). a reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.